Scientific Programme

FRIDAY 8 JUNE 2018

10:00 - 11:35

HBV Cure Overview

 

10:00 – 10:15

Opening lecture: HBV cure and the WHO elimination target

 

10:15 – 10:30

International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) update 2018           

 

10:30 – 10:45

HBV Forum: update 2018

 

10:45 – 11:00

Lessons from a HIV cure program   

 

11:00 – 11:15

What can we learn from animal models of CHB

 

11:15 – 11:35

Discussion forum led by the Moderator

11:35 - 12:15

 Lunch

12:15 - 13:15

Clinical & Translational Forum

 

12:15 – 12:30

Viral evolution and immune interaction in HBV 

 

Invited Oral & Free Paper Presentations

 

12:30 – 12:45

Development of novel markers of treatment response

 

12:45 – 12:55

Splice variants in HBV

 

12:55 – 13:15

Discussion forum led by the Moderator

13:15 - 14:30

Viral Transcription

 

13:15 – 13:30

Transcriptional targets for HBV

 

Invited Oral & Free Paper Presentations

 

13:30 – 13:45

What can we learn from interferon in HBV cure?

 

13:45 – 14:00

Role of cAg in cccDNA

 

14:00 – 14:10

Free paper

 

14:10 – 14:30

Discussion forum led by the Moderator

14:30 – 15:35

Capsid inhibition

 

14:30 – 14:45

Mechanism and efficacy of capsid inhibitors

 

Invited Oral & Free Paper Presentations

 

14:45 – 14:55

Janssen

 

14:55 – 15:05

Roche

 

15:05 – 15:15

Arbutus

 

15:15 – 15:35

Discussion forum led by the Moderator

15:35 – 15:50

 Tea Break

15:50 – 16:25

Special Lecture

 

15:50 – 16:05

Can blocking viral entry lead to HBV functional cure?

 

16:05 – 16:25

Discussion forum led by the Moderator

16:45 – 17:50

Reducing Viral Antigens

 

16:25 – 16:40

Can reduction in viral antigens lead to immune reconstitution?

 

Invited Oral & Free Paper Presentations

 

16:40 – 16:50

Arrowhead

 

16:50 – 17:00

Arbutus

 

17:00 – 17:10

Roche

 

17:10 – 17:20

GSK

 

17:20 – 17:30

Replicor

 

17:30 – 17:50

Discussion forum led by the Moderator

 

End of Day 1

 

SATURDAY 9 JUNE 2018

09:00 – 09:50

Debate: HBV can be cured by antiviral therapy alone?

09:00 – 09:30

Yes:    No:     

09:30 – 09:50

Discussion forum led by the Moderator

09:50 – 11:20

Immunology Forum Part 1

09:50 – 10:05

Assays to assess HBV immune function and HBV clearance

10:05 – 10:20

Intrahepatic Immunology in HBV clearance

Invited Oral & Free Paper Presentations

10:20 – 10:35

Evidence of innate immunity in viral clearance in CHB

10:35 – 10:45

Gilead Sciences

10:45 – 10:55

Springbank

10:55 – 11:20

Discussion forum led by the Moderator

11:20 -11:35

Tea Break

11:35 – 13:10

Immunology Forum Part 2

11:35 – 11:50

T cell phenotyping in CHB and viral clearance?

11:50 – 12:05

Characteristics of immune clearance of HBV in Chronic Hepatitis B

Invited Oral & Free Paper Presentations

12:05 – 12:20

Meta-analysis of Therapeutic Vaccination for CHB

12:20 – 12:35

Neutralising antibodies in CHB

12:35 – 12:50

Evidence for B cell activity in CHB

12:50 – 13:10

Discussion forum led by the Moderator

13:10 – 14:00

Lunch

14:00 – 16:15

Combination Therapy Forum

 

14:00 – 14:15

Summary of HBV Forum combination therapy workgroup

Round Table discussion

14:15 – 16:15

Do we need combination therapy for virological targets to achieve functional cure?

16:15 – 16:30

Tea Break

16:30 – 17:30

16:30 – 16:45

Innate or adaptive immunology or combination therapy for functional cure?

16:45 – 17:30

Combination therapy forum:

17:30

Conclusion